Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Strong near-term momentum with a fresh high on 2026-07-22, major Q1 2026 turnaround to high margins and strong cash flow, YUTREPIA commercial traction, and S&P SmallCap 600 inclusion effective 2026-06-22.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Profitability Rebound ⢠Strong Cash Flow ⢠Improved Liquidity LQDA's sharp return to profitability, cash generation, and net-cash liquidity is encouraging, but elevated valuation multiples and historical balance-sheet weakness warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Persistent downtrend ⢠Testing support ⢠Below average Support Level: $66.70â$66.90 Resistance Level: $69.70â$70.50 LQDA remains bearish over the last month, with support at $66.70â$66.90 needing to hold to avoid further downside and resistance at $69.70â$70.50 limiting rebound potential.
Sentiment & News
Key News Insights: ⢠Strong Yutrepia sales ⢠Margin expansion ⢠Litigation overhang Liquidia's strong Yutrepia sales and margins support growth ambitions, but litigation, competition, slowing adoption concerns, and single-product reliance weigh on LQDA's outlook.
AI Summary
LQDA has re-rated into a high-margin, cash-generative YUTREPIA franchise, but at premium multiples the actionable question is whether sales momentum can persist through patent litigation and slowing prescriber acquisition; maintain conviction only if growth and legal durability validate the $1B 2027 revenue path.
Description
Liquidia Corporation is a U.S.-based biopharmaceutical company that develops, manufactures and commercializes therapies to address unmet clinical needs. Its portfolio includes an inhaled dry powder formulation of treprostinil for pulmonary arterial hypertension and it also markets generic treprostinil injection domestically. The company was founded in 2004 and is headquartered in Morrisville, North Carolina.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 22 | Jul 29 | LQDA | Liquidia Corporation | Strong near-term momentum with a fresh high on 2026-07-22, major Q1 2026 turnaround to high margins and strong cash flow, YUTREPIA commercial traction, and S&P SmallCap 600 inclusion effective 2026-06-22. | Closed | -0.3% |
| Jul 6 | Jul 13 | LQDA | Liquidia Corporation | Commercial and technical momentum are strong: Q1 2026 included about $130M in YUTREPIA net sales, over 4,500 unique prescriptions, a third straight profitable quarter, and positive cash generation. S&P SmallCap 600 inclusion effective 2026-06-22 adds visibility, and shares are up about 30% over 21 trading days. | Closed | -10.1% |
| Jun 23 | Jun 30 | LQDA | Liquidia Corporation | Strong healthcare momentum with shares up about 24% over 21 trading days and at a new closing high, supported by Q1 2026 YUTREPIA net product sales around $130M, a third straight profitable quarter, positive free cash flow, and S&P SmallCap 600 inclusion. | Closed | +7.7% |
| Jun 16 | Jun 23 | LQDA | Liquidia Corporation | Constructive biotech momentum with a near-term index catalyst: Q1 2026 net product sales were about $130M, the company posted a third consecutive profitable quarter, and S&P SmallCap 600 inclusion is effective 2026-06-22. Shares are up about 20% over 21 trading days and remain above short-term trend. | Closed | +8.9% |
| Jun 8 | Jun 15 | LQDA | Liquidia Corporation | Commercial biotech momentum supported by strong YUTREPIA execution: latest quarter showed about $130M in net product sales, EPS beat consensus ($0.52 vs. $0.34), profitability improved for a third straight profitable quarter, and the stock is up about 50% over 21 trading days. | Closed | +12.4% |
| Jun 1 | Jun 8 | LQDA | Liquidia Corporation | Biotech/commercial momentum name with strong recent execution: YUTREPIA sales were about $130M-$133M, prescriptions exceeded 4,500, profitability reached a third straight quarter, adjusted EBITDA was positive, and free cash flow was strong. Stock is up about 56% over 21 trading days. | Closed | +8.8% |
| May 22 | May 29 | LQDA | Liquidia Corporation | Strong biotech execution and momentum: Q1 2026 showed about $130M of YUTREPIA net sales, more than 4,500 unique prescriptions, a third straight profitable quarter, and improved cash; stock is up about 66% over 21 trading days. | Closed | +1.4% |
| May 13 | May 20 | LQDA | Liquidia Corporation | Strong operating inflection and price momentum: Q1 2026 YUTREPIA net product sales were about $130M, with more than 4,500 unique prescriptions, a third straight profitable quarter, net income around $53M, adjusted EBITDA of $71M, and free cash flow near $50M. Shares are up about 41% over 21 trading days. | Closed | +7.3% |